German pharmaceutical giant Boehringer Ingelheim (BI) is building a new $65m R&D facility at its US headquarters in Ridgefield, Connecticut.
The new facility, according to BI, will undertake “production of active pharmaceutical ingredients used in early development activities”.
While not employing new staff, the new R&D site – which will replace a smaller current site – will support the company’s research activity in the region.
This development follows another new building project in Ridgefield commenced by BI in August: a $42m drug safety assessment site for non-clinical safety studies, scheduled for completion in 2013.
The two new buildings represent a total investment of more than $100 million in the Connecticut operation.
Jim Baxter, BI’s Senior VP of Development for US Operations, said that the company’s investment in new buildings shows its commitment to supporting and developing its US research base: “When they say the site is critical to BI’s future, they mean it.”
Boehringer Ingelheim has invested more than $350 million in the US in 2011, with new projects in Iowa, Missouri and Ohio and the acquisition of a business from Amgen in California.